The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: A change in national treatment guidelines may be warranted

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 5, 2013, Pages 540-545

  Zhang, Chengda ^a   Wang, Wei ^a   Zhou, Mengyu ^a   Han, Yang ^a   Xie, Jing ^a   Qiu, Zhifeng ^a   Guo, Fuping ^a   Li, Yanling ^a   Wang, Huanling ^a   Ghanem, Khalil G ^b   Li, Taisheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD4 lymphocyte count; Drug toxicity; Hepatotoxicity; Nevirapine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CD4 LYMPHOCYTE COUNT; CHINA; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; NEVIRAPINE; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84876411661     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182845cc7     Document Type: Article

References (25)

1. Li T, Dai Y, Kuang J, et al. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. PLoS One. 2008;3:e3918.
2. Zhang F, Li T, Wang Y, et al. National Guide for Free Antiviral Treatment Of HIV Patients. Beijing, China: People's Medical Publishing House; 2007.
3. Viramune tablets and oral suspension, US [package insert]. Ingelheim, German: Boehringer Ingelheim; 2006.
4. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34(suppl 1):S21-S33.
5. Torti C, Costarelli S, De Silvestri A, et al. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. Drug Saf. 2007;30:1161-1169.
6. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med. 2006;7:255-260.
7. Peters PJ, Stringer J, McConnell MS, et al. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ./=250 cells/mL among women in Zambia, Thailand and Kenya. HIV Med. 2010;11: 650-660.
8. Bottaro EG, Huberman MJ, Iannella MC, et al. Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina. J Int Assoc Physicians AIDS Care (Chic). 2010;9:306-312.
9. Chu KM, Boulle AM, Ford N, et al. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS One 2010;5: e9183.
10. Phanuphak N, Apornpong T, Teeratakulpisarn S, et al. Nevirapine- associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med. 2007;8:357-366.
11. Peters PJ, Polle N, Zeh C, et al. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya. J Int Assoc Physicians AIDS Care (Chic). 2012;11:142-149.
12. Marazzi MC, Germano P, Liotta G, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med. 2006;7: 338-344.
13. Wang H, Li Y, Zhang C, et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. AIDS. 2012;26:1755-1763.
14. World Health Organization. Toxicity grading scale for determining the severity of adverse events. Available at: http://www.icssc.org/Documents/ Resources/AEManual2003AppendicesFebruary-06-2003%20final.pdf. Accessed December 9, 2011.
15. Antunes AM, Novais DA, Da SJ, et al. Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine. Org Biomol Chem. 2011;9:7822-7835.
16. Bonnet F, Lawson-Ayayi S, Thiebaut R, et al. A cohort study of nevirapine tolerance in clinical practice: French aquitaine cohort, 1997-1999. Clin Infect Dis. 2002;35:1231-1237.
17. Dieterich DT, Robinson PA, Love J, et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38(suppl 2):S80-S89.
18. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005; 191:825-829.
19. Baylor MS, Johann-Liang R, Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35:538-539.
20. Kalyesubula R, et al. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci. 2011;11:16-23.
21. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
22. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIVinfected patients. J Infect Dis. 2007;196:670-676.
23. Ocama P, Castelnuovo B, Kamya MR, et al. Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS. 2010;21:553-557.
24. Palmon R, Koo BC, Shoultz DA, et al. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:340-345.
25. Mbougua JB, Laurent C, Kouanfack C, et al. Hepatotoxicity and effectiveness of a nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health. 2010;10:105.